Accelr8 Technology Corporation announced that the company received notice of an ICAAC Program Committee Award in the area of Clinical Microbiology and Diagnosis. The award recognizes the "outstanding presentation of an abstract accepted by ICAAC" for the 51st ICAAC to be held in Chicago on September 17-20, 2011. The award will be presented at the meeting. The presentation title is "Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy." It will report results from a study using Accelr8's BACcel(TM) rapid diagnostic system in collaboration with investigators at the Barnes-Jewish Hospital in St. Louis.
Accelr8 will announce the study results at the time of the presentation.
ICAAC ( www.icaac.org ) is the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Organized by the American Society for Microbiology ( www.asm.org ), ICAAC is a major global congress for Clinical Microbiology and Infectious Diseases Medicine.
In additional news, Accelr8 received notice of issuance for a Japanese patent on the BACcel(TM) system. The new patent joins previously issued US and international patents to broaden Accelr8's global patent coverage for the BACcel(TM) system.
According to David Howson, Accelr8's president, "We are honored by the recognition from ICAAC's review committee. It reflects the BACcel(TM) system's potential importance in Clinical Microbiology. Our culture-free methods have repeatedly demonstrated the unprecedented ability to quantitatively identify multiple pathogens directly from patient specimens in less than 2 hours. Our pilot clinical studies pass the 'real specimen' hurdle that continues to stymie new attempts to replace multi-day culturing. The BACcel(TM) system continues to widen its lead in helping to fight the worsening global antibiotic resistance pandemic."